Suppr超能文献

血管内修复治疗腹主动脉瘤的结果:日本全国性调查。

Outcomes of Endovascular Repair for Abdominal Aortic Aneurysms: A Nationwide Survey in Japan.

机构信息

Department of Vascular Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Division of Cardiovascular Surgery, Department of Surgery, Toda Chuo General Hospital, Saitama, Japan.

出版信息

Ann Surg. 2019 Mar;269(3):564-573. doi: 10.1097/SLA.0000000000002508.

Abstract

OBJECTIVE

To analyze data on patients treated with a bifurcated stent graft for abdominal aortic aneurysm (AAA).

BACKGROUND

The Japan Committee for Stentgraft Management (JACSM) was established in 2007 to manage the safety of endovascular aortic aneurysm repair (EVAR) in Japan. The JACSM registry includes detailed anatomical and clinical data of all patients who undergo stent graft insertion in Japan.

METHODS

Among 51,380 patients treated with bifurcated stent graft for AAA, we identified 38,008 eligible patients (excluding those with rupture or insufficient data). The analyzed factors included age, sex, comorbidities, AAA pathology and etiology, aneurysm and neck diameters, 7 anti-instructions for use (IFU) factors, and endoleaks at hospital discharge. The endpoints were death, adverse events, sac dilatation (≥5 mm), and reintervention.

RESULTS

The rates of intraoperative and in-hospital mortality were 0.08% and 1.07%, respectively. Infectious aneurysm and pseudo-aneurysm were associated with overall survival and reintervention. Older age, large aneurysm diameter, and all types of persistent endoleaks were strong predictors of adverse events, sac dilatation, and reintervention. Comorbid cerebrovascular disease, renal dysfunction, and respiratory disorders were also risk factors. In total, 47.6% of patients violated the IFU; among the anti-IFU factors assessed, poor access and severe neck calcification were strong risk factors for mortality, reintervention, and adverse events. The sac dilatation rate at 5 years was 23.3%.

CONCLUSIONS

Although the analysis included EVAR with poor anatomy, the perioperative mortality rate was acceptable compared with that in previous large population studies.

摘要

目的

分析接受分叉支架移植物治疗腹主动脉瘤(AAA)患者的数据。

背景

日本支架管理委员会(JACSM)成立于 2007 年,负责管理日本腔内血管修复术(EVAR)的安全性。JACSM 注册中心包含了所有在日本接受支架移植物置入的患者的详细解剖学和临床数据。

方法

在接受分叉支架移植物治疗 AAA 的 51380 例患者中,我们确定了 38008 例符合条件的患者(不包括破裂或数据不足的患者)。分析的因素包括年龄、性别、合并症、AAA 病理和病因、瘤颈和瘤囊直径、7 项使用说明书(IFU)因素以及出院时的内漏。终点包括死亡、不良事件、瘤囊扩张(≥5mm)和再次干预。

结果

术中死亡率和住院死亡率分别为 0.08%和 1.07%。感染性动脉瘤和假性动脉瘤与总生存和再次干预有关。年龄较大、瘤囊直径较大以及所有类型的持续性内漏是不良事件、瘤囊扩张和再次干预的强烈预测因素。合并脑血管疾病、肾功能不全和呼吸障碍也是危险因素。共有 47.6%的患者违反了 IFU;在评估的反 IFU 因素中,入路不良和严重的颈部钙化是死亡、再次干预和不良事件的强烈危险因素。5 年的瘤囊扩张率为 23.3%。

结论

尽管分析包括解剖结构较差的 EVAR,但与之前的大型人群研究相比,围手术期死亡率是可以接受的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b18/6369872/4e431e0822e7/ansu-269-564-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验